Table 5.
Number of studies reporting parameters which could influence the cost-effectiveness results
| Therapeutic area | Epidemiological and disease progression parameters | Clinical effectiveness data | Resource use and cost parameters | ||||||
|---|---|---|---|---|---|---|---|---|---|
| probability of ADRs | allele frequency | PPV/NPV | mortality rate of ADRs | efficacy of genetic testing | efficacy of drugs treatment | cost of testing | costs of alternative drugs | cost of hospitalization | |
| Cardiovascular disease (n = 24) | |||||||||
| CYP2C19 -Clopidogrel | [30, 33, 34] | [31] | [35] | [36] | [38] | ||||
| CYP2C9 and VKORC1 -Warfarin | [17, 21, 25] | [16, 22, 26, 28, 29] | [23, 24] | [19] | |||||
| pharmacogenetic testing-Statin | [39] | ||||||||
| Gout (n = 8) | |||||||||
| HLA-B*58:01 -Allopurinol | [43, 44, 46] | [45] | [40] | [42] | [44] | [40, 47] | |||
| HIV infection (n = 8) | |||||||||
| HLA-B*57:01 -Abacavir | [50] | [49] | [51, 52] | [53, 54] | |||||
| CYP2B6 -Efavirenz | [55] | ||||||||
| Autoimmune disease (n = 8) | |||||||||
| TPMT - Azathioprine | [57] | [62] | [63] | [56, 58] | [60] | ||||
| Epilepsy/neuropathic pain (n = 6) | |||||||||
| HLA-B*15:02 or HLA-A*31:01 -Carbamazepine | [67, 68] | [64, 69] | [65, 67] | ||||||
| Cancer (n = 3) | |||||||||
| UGT1A1 -Irinotecan | [71] | [72] | |||||||
| DPYD -Fluoropyrimidine | [70] | ||||||||
| Major depressive disorder (n = 1) | |||||||||
| CYP2D6 -Nortriptyline | [73] | [73] | |||||||
| Hormone replacement therapy (n = 1) | |||||||||
| Factor V Leiden-Estrogen combined in oral contraceptives | |||||||||
ADRs: Adverse Drug Reactions, PPV: Positive Predictive Value, NPV: Negative Predictive Value